> top > docs > PMC:7205724 > spans > 295-603 > annotations

PMC:7205724 / 295-603 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
5 36-44 Disease denotes COVID-19 MESH:C000657245
7 119-127 Disease denotes COVID-19 MESH:C000657245
10 132-135 Gene denotes IL6 Gene:3569
11 204-212 Disease denotes COVID-19 MESH:C000657245
17 238-241 Gene denotes IL6 Gene:3569
18 297-300 Gene denotes IL6 Gene:3569
19 265-273 Species denotes patients Tax:9606
20 217-228 Chemical denotes Tocilizumab MESH:C502936
21 279-287 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T2 36-44 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 119-127 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 204-212 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 279-287 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T5 99-114 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T2 175-185 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes viral load http://purl.bioontology.org/ontology/MEDDRA/10062178

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T4 99-114 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T2 36-44 Species denotes COVID-19 NCBItxid:2697049
T3 119-127 Species denotes COVID-19 NCBItxid:2697049
T4 204-212 Species denotes COVID-19 NCBItxid:2697049
T5 279-287 Species denotes COVID-19 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T7 46-128 Sentence denotes • No controlled clinical trials exist on the use of corticosteroids for COVID-19.
T8 129-213 Sentence denotes • IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.
T9 214-301 Sentence denotes • Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
5 36-44 Disease denotes COVID-19 MESH:C000657245
7 119-127 Disease denotes COVID-19 MESH:C000657245
10 132-135 Gene denotes IL6 Gene:3569
11 204-212 Disease denotes COVID-19 MESH:C000657245
20 217-228 Chemical denotes Tocilizumab MESH:C502936
17 238-241 Gene denotes IL6 Gene:3569
19 265-273 Species denotes patients Tax:9606
21 279-287 Disease denotes COVID-19 MESH:C000657245
18 297-300 Gene denotes IL6 Gene:3569

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T1 132-135 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T45 238-241 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T89 297-300 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T42 5-10 MD denotes might
T43 11-21 VB denotes accelerate
T44 22-30 NN denotes recovery
T45 31-35 IN denotes from
T46 36-44 NN denotes COVID-19
T47 46-47 PDT denotes •
T48 49-51 DT denotes No
T49 52-62 VBN denotes controlled
T50 63-71 JJ denotes clinical
T51 72-78 NNS denotes trials
T52 79-84 VBP denotes exist
T53 85-87 IN denotes on
T54 88-91 DT denotes the
T55 92-95 NN denotes use
T56 96-98 IN denotes of
T57 99-114 NNS denotes corticosteroids
T58 115-118 IN denotes for
T59 119-127 NN denotes COVID-19
T60 129-130 LS denotes •
T61 132-135 NN denotes IL6
T62 136-146 VBZ denotes correlates
T63 147-151 IN denotes with
T64 152-160 NN denotes severity
T65 160-161 -COMMA- denotes ,
T66 162-173 NN denotes criticality
T67 173-174 -COMMA- denotes ,
T68 175-180 JJ denotes viral
T69 181-185 NN denotes load
T70 185-186 -COMMA- denotes ,
T71 187-190 CC denotes and
T72 191-200 NN denotes prognosis
T73 201-203 IN denotes of
T74 204-212 NN denotes COVID-19
T75 214-215 IN denotes •
T76 217-228 NNP denotes Tocilizumab
T77 228-229 -COMMA- denotes ,
T78 230-232 DT denotes an
T79 233-241 NN denotes anti-IL6
T80 241-242 -COMMA- denotes ,
T81 243-246 MD denotes can
T82 247-253 VB denotes confer
T83 254-261 NN denotes benefit
T84 262-264 IN denotes in
T85 265-273 NNS denotes patients
T86 274-278 IN denotes with
T87 279-287 NN denotes COVID-19
T88 288-291 CC denotes and
T89 292-296 JJ denotes high
T90 297-300 NN denotes IL6
R38 T43 T42 arg2Of accelerate,might
R40 T44 T43 arg2Of recovery,accelerate
R41 T44 T45 arg1Of recovery,from
R42 T46 T45 arg2Of COVID-19,from
R43 T51 T47 arg1Of trials,•
R44 T51 T48 arg1Of trials,No
R45 T51 T49 arg2Of trials,controlled
R46 T51 T50 arg1Of trials,clinical
R47 T51 T52 arg1Of trials,exist
R48 T52 T53 arg1Of exist,on
R49 T55 T53 arg2Of use,on
R50 T55 T54 arg1Of use,the
R51 T55 T56 arg1Of use,of
R52 T57 T56 arg2Of corticosteroids,of
R53 T55 T58 arg1Of use,for
R54 T59 T58 arg2Of COVID-19,for
R55 T62 T60 arg1Of correlates,•
R56 T61 T62 arg1Of IL6,correlates
R57 T62 T63 arg1Of correlates,with
R58 T71 T63 arg2Of and,with
R59 T64 T65 arg1Of severity,","
R60 T66 T65 arg2Of criticality,","
R61 T65 T67 arg1Of ",",","
R62 T69 T67 arg2Of load,","
R63 T69 T68 arg1Of load,viral
R64 T71 T70 arg1Of and,","
R65 T67 T71 arg1Of ",",and
R66 T72 T71 arg2Of prognosis,and
R67 T72 T73 arg1Of prognosis,of
R68 T74 T73 arg2Of COVID-19,of
R69 T82 T75 arg1Of confer,•
R70 T76 T77 arg1Of Tocilizumab,","
R71 T79 T77 arg2Of anti-IL6,","
R72 T79 T78 arg1Of anti-IL6,an
R73 T82 T80 arg1Of confer,","
R74 T76 T81 arg1Of Tocilizumab,can
R75 T82 T81 arg2Of confer,can
R76 T76 T82 arg1Of Tocilizumab,confer
R77 T83 T82 arg2Of benefit,confer
R78 T82 T84 arg1Of confer,in
R79 T85 T84 arg2Of patients,in
R80 T85 T86 arg1Of patients,with
R81 T88 T86 arg2Of and,with
R82 T87 T88 arg1Of COVID-19,and
R83 T90 T88 arg2Of IL6,and
R84 T90 T89 arg1Of IL6,high

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T2 36-44 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 119-127 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 204-212 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 279-287 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T7 46-128 Sentence denotes • No controlled clinical trials exist on the use of corticosteroids for COVID-19.
T8 129-213 Sentence denotes • IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19.
T9 214-301 Sentence denotes • Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.